Navigation Links
Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/14/2012

SAN MATEO, Calif., March 14, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session, March 24-26th. Location: McCormick Place South, Hall A Date: Monday, March 26, 2012 Time: 10:00 AM -12:00 PM (CT) Poster Presentation: Board #628  Presenter: Hsiao D. Lieu, MD, FACC Title: "Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure"About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the annual inpatient cost of heart failure.

About Nile TherapeuticsNile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. The cenderitide program was granted Fast Track status by the United States Food and Drug Administration. More information on Nile can be found at http://www.nilethera.com.


'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
2. ADHD Therapeutics Reviewed by NeuroPerspective
3. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
4. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
5. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
6. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
7. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
8. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
9. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
10. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
11. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Research and Markets has announced the addition of the ... Product (RFID refrigerators and RFID freezers), Application (Diagnostic centers, Blood banks ... ... RFID Blood Refrigerator and Freezer Market is poised to grow at ... This industry report analyzes the global markets for RFID Blood ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... 20, 2017 Adequate intake of ... phosphorous minerals in one,s body. Consumers are well aware ... maintaining a healthy composition of bones and teeth. Consumption ... is growing in the world. Medical research and clinical ... ingredients for treatment of prevalent disorders such as multiple ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... will join forces with Healthwise ® at HIMSS 2017 to ... leader in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge ...
(Date:2/18/2017)... ... 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has been ... Radio network. The episode, which was posted this week, features a 30-minute interview ... to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation (AHF) ... further positively impact the health and wellness of our community in San Diego ... duty to seriously consider releasing our assets beyond our 5% targeted distribution each ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):